ArticleCase reports in women's health2026
Therapeutic challenges in the management of chronic myeloid leukemia during pregnancy: A report of two cases.
Article in Case reports in women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic myeloid leukemia (CML) during pregnancy is a rare clinical condition that poses significant therapeutic challenges, as maternal disease control must be balanced against fetal safety. Evidence-based management guidelines remain limited, particularly in settings with restricted access to pregnancy-compatible therapies. This report presents two cases of pregnant patients with chronic-phase CML who conceived without adequate hematologic control due to irregular tyrosine kinase inhibitor therapy and lack of access to interferon-alpha. The first case involved a woman at 33 weeks of gestation requiring an urgent preterm cesarean delivery for nonreassuring fetal status, complicated by significant postoperative hemoperitoneum, while her neonate required a prolonged stay in an intensive care unit. The second case concerned a patient at 25 weeks of gestation who was successfully managed with cytoreductive therapy using cytarabine, achieving hematologic stabilization and term delivery, though complicated by immediate postpartum hemorrhage. In both cases, treatment was guided by multidisciplinary decision-making and local availability of treatments. These cases demonstrate that CML during pregnancy carries a high risk of adverse maternal and perinatal outcomes when preconception counseling is absent, disease control is suboptimal, and access to recommended first-line therapies is unavailable. The clinical experience emphasizes the importance of individualized multidisciplinary care, robust family-planning counseling, and equitable access to safe, effective therapies to optimize outcomes for both mother and fetus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.